AI Therapeutics Announces Name Change to OrphAI Therapeutics
28 sept. 2023 11h38 HE
|
AI Therapeutics, Inc.
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
11 sept. 2023 08h00 HE
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference
09 mai 2023 10h38 HE
|
AI Therapeutics, Inc.
GUILFORD, Conn., May 09, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today Dr Antje Prasse...
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
30 mars 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
09 nov. 2022 08h00 HE
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
27 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15 août 2022 16h00 HE
|
aTyr Pharma, Inc.
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the...
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
13 sept. 2021 07h30 HE
|
aTyr Pharma, Inc.
Pangu’s basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical...
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
13 sept. 2021 07h30 HE
|
aTyr Pharma, Inc.
Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the...
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
10 août 2021 08h00 HE
|
aTyr Pharma, Inc.
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE)...